Slide

Your Partner in Life Sciences Transformation

The Dedham Group is a top-tier strategy consulting firm to propel you toward unparalleled commercial success.

With robust data, highly specialized expertise, and 360-degree perspective on the stakeholder experience, we are your go-to partner to transform commercial models, revamp market positioning, and ensure better patient access to care.

Learn More

Unparalleled Results

Our expert think-tank cuts through the “noise” to unearth actionable insights and cross-functional strategic recommendations to shatter payer, provider and patient access barriers.

Expert Insights

With over two decades of experience in the most complex healthcare categories, our dedicated teams of subject matter experts in oncology, immunology, rare disease, and other specialty spaces are in a league of their own.

Consider us your preferred partners for strategic direction across payer, provider, distribution and support channels, with a focus in access, pathways, pricing, contracting and customer engagement.

Let’s elevate your market access journey together.

Customer-Centric & Client-First

We prioritize your success, elevating your internal and external positioning to fuel commercial excellence.

Our relationship-driven business delivers a white-glove experience, with high-touch expert support in simplifying our complex access environment.

“With so much change and noise, it’s hard to focus our people and resources, and no one is closer to the customer than Dedham, which gives us a huge competitive edge on a daily basis.”

VP, Oncology Franchise

"The Dedham Group is very data-driven and their output is always actionable because they know how to help us implement…we rely heavily on them as a priority partner."

Executive Director, Market Access

Breaking Down Barriers,
One Client, One Story at a Time

State Drug Importation Programs: Key Considerations for Manufacturers

By Aaron McKeon-Fish In the government’s ongoing pursuit of lower drug prices for American patients, the FDA’s Drug Importation Program, approved in Florida in January, allows states to import prescription drugs from Canada, where prices can be meaningfully lower. As the first of its kind, its implementation has already driven interest among eight other states, […]

Evolving Payer Pressures on Patient Affordability: How Pharma Can Improve Access with Support Program Evolution

By Rebecca Leemputte For some patients who are prescribed specialty therapies, insurance coverage limitations or cost share requirements prevent them from accessing necessary treatments. Manufacturer patient support programs (PSPs) play a critical role in addressing payer coverage gaps and ensuring treatments are affordable for patients. PSPs provide resources to facilitate access – from benefits investigation […]

What Private Equity’s Growing Role in Urology Practices Means for Oncology Manufacturers

Over the past five years, private equity groups have slowly increased their acquisition of urology practices, increasing their footprint and influence in the urology channel. While many debate the impact of private equity on healthcare delivery and quality, the PE footprint across U.S. healthcare is expected to grow consistently over the next few years.

Unlocking the Pathway Puzzle: How Biopharma Can Navigate the Clinical Pathways Landscape

In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, multidisciplinary, and cost-effective approaches. Pathways have become a critical strategy for both physicians and payers to streamline treatment decision-making, standardize evidence-based care, improve patient outcomes by minimizing unnecessary variation, and reduce cost by guiding care to the most cost-effective treatments.

Urology Practices’ Growing Role in Oncology: 3 Trends to Watch

In 2024, urology practices continue to expand their role in the oncology treatment space, and proactive pharma companies are increasingly focusing on this channel. Historically, urology practices directed their patients to specialized oncology practices and academic care centers for treatment of advanced genitourinary (GU) cancers, such as prostate cancer or urothelial carcinoma.

Four Trends That Are Shaping the Future of Market Access

Today’s guest post comes from James Pisano, Partner, Market Access at The Dedham Group and Dinesh Kabaleeswaran, SVP of Insights & Advisory Teams at MMIT

3 Key Challenges Discussed at Cell & Gene Meeting on the Mesa

At the 2023 Cell & Gene Meeting on the Mesa earlier this month, senior executives and top decision-makers discussed commercialization challenges facing the cell and gene therapy sector. This year’s conference called out some of the biggest issues that the industry is facing.

10 Questions that Oncology Manufacturers Should Be Asking About the Stark Law

Even though we knew it was coming, the end of the COVID public health emergency (PHE) on May 11, 2023, still took the healthcare industry by surprise. While the end of the PHE resulted in the rollback of many COVID-19 programs, it also changed the ways that Medicare patients can access oral therapies from community oncology clinics.

5 Barriers to Access for Sickle Cell Disease Gene Therapies

Sickle cell disease (SCD) is a genetic blood disorder that affects the lives of 100,000 Americans1. SCD causes abnormal hemoglobin molecules in the red blood cells, resulting in cells forming in a crescent or sickle shape, which can block blood vessels and cause pain, organ damage, and other complications.